SpinalMotion, developer of investigational artificial discs for treating patients with degenerative disc disease, today reported significant progress on two clinical trials aimed at evaluating its Kineflex(TM) lumbar disc and Kineflex/C(TM) cervical disc implants. Earlier this year, the company received Investigational Device Exemption (IDE) approvals from the U.S. Food & Drug Administration (FDA) to commence the studies, which began during the second quarter. As of now, over 80 patients are enrolled in the U.S.-based studies, bringing to over 600 the number of patients worldwide implanted with a Kineflex disc. The company is also expected to close a $5 million growth capital line next month.
